Alpha-synuclein single domain antibodies
AssigneeNew York University
InventorEinar M. SIGURDSSON
Life of this patent
Estimating the term…
Abstract
The present disclosure is directed to single domain antibodies that bind to α-synuclein and the use of these antibodies for the treatment and diagnosis of α-synucleinopathies The present disclosure is also directed to polynucleotides encoding the α-synuclein single domain antibodies, therapeutic vectors comprising these polynucleotides and methods of administering these therapeutic vectors for the treatment of α-synucleinopathies.
Claims40
An antibody or fragment thereof, said antibody or binding fragment thereof comprising a heavy chain variable region, wherein said heavy chain variable region comprises:
- a complementarity-determining region 1 (H-CDR1) comprising an amino acid sequence of any one of SEQ ID NOs:
- 1-36, 218, 222, 226, 230, 234, 238, 340 or a modified amino acid sequence of any one of SEQ ID NOs:
- 1-36, 218, 222, 226, 230, 234, 238, and 340 said modified sequence containing 1, 2, or 3 amino acid residue modifications as compared to any one of SEQ ID NOs:
- 1-36, 218, 222, 226, 230, 234, 238, and 340;
- a complementarity-determining region 2 (H-CDR2) comprising an amino acid sequence of any one of SEQ ID NOs:
- 37-72, 219, 223, 227, 231, 235, 239, 341 or a modified amino acid sequence of any one of SEQ ID NOs:
- 37-72, 219, 223, 227, 231, 235, 239, and 341 said modified sequence containing 1, 2, or 3 amino acid residue modifications as compared to any one of SEQ ID NOs:
- 37-72, 219, 223, 227, 231, 235, 239, and 341;
- and
- a complementarity-determining region 3 (H-CDR3) comprising an amino acid sequence of any one of SEQ ID NOs:
- 73-108, 220, 224, 228, 232, 236, 240, 342 or a modified amino acid sequence of any one of SEQ ID NOs:
- 73-108, 220, 224, 228, 232, 236, 240, and 342 said modified sequence containing 1, 2, or 3 amino acid residue modifications as compared to any one of SEQ ID NOs:
- 73-108, 220, 224, 228, 232, 236, 240, 342.
(canceled)
(canceled)
An antibody or fragment thereof, said antibody or binding fragment thereof comprising a heavy chain variable region, wherein said heavy chain variable region comprises:
- a complementarity-determining region 1 (H-CDR1) comprising an amino acid sequence of any one of SEQ ID NOs:
- 146-160, or a modified amino acid sequence of any one of SEQ ID NOs:
- 146-160, said modified sequence containing 1, 2, or 3 amino acid residue modifications as compared to any one of SEQ ID NOs:
- 146-160;
- a complementarity-determining region 2 (H-CDR2) comprising an amino acid sequence of any one of SEQ ID NOs:
- 161-175, or a modified amino acid sequence of any one of SEQ ID NOs:
- 161-175, said modified sequence containing 1, 2, or 3 amino acid residue modifications as compared to any one of SEQ ID NOs:
- 161-175;
- and
- a complementarity-determining region 3 (H-CDR3) comprising an amino acid sequence of any one of SEQ ID NOs:
- 176-190, or a modified amino acid sequence of any one of SEQ ID NOs:
- 176-190, said modified sequence containing 1, 2, or 3 amino acid residue modifications as compared to any one of SEQ ID NOs:
- 176-190.
(canceled)
(canceled)
-36. (canceled)
-40. (canceled)
-45. (canceled)
Dependencies are inferred from the claim text.